

**Supplemental Table 1. Basic characteristics of patients taking different statin dosages**

mean ± SD		0.4 ± 0.8		0.8 ± 1.2		0.9 ± 1.3		1.0 ± 1.3		1.1 ± 1.4	<0.001 <sup>b</sup>	<0.001 <sup>‡</sup>
0	125655	76.4	1037	57.3	935	51.4	882	47.9	777	43.9	<0.001 <sup>d</sup>	
1	25547	15.5	437	24.1	509	28.0	520	28.3	503	28.4		
2	8485	5.2	195	10.8	197	10.8	235	12.8	228	12.9		
≥3	4767	2.9	141	7.8	177	9.7	204	11.1	261	14.8		

#### Monthly income

(USD)

≤600	79098	48.1	983	54.3	1005	55.3	1064	57.8	1074	60.7	<0.001 <sup>d</sup>
600 - 1,400	62954	38.3	624	34.5	609	33.5	567	30.8	519	29.3	
>1,400	22402	13.6	203	11.2	204	11.2	210	11.4	176	10.0	

#### Living area

Urban	101983	62.0	1118	61.8	1157	63.6	1195	64.9	1193	67.4	<0.001 <sup>d</sup>
Suburban	21874	13.3	252	13.9	239	13.2	241	13.1	228	12.9	

Rural	40597	24.7	440	24.3	422	23.2	405	22.0	348	19.7
-------	-------	------	-----	------	-----	------	-----	------	-----	------

---

Characteristics, including age, sex, the CCI, monthly income, and living area, of the recruited patients taking different dosages of statin are displayed.

<sup>a</sup> Q1: Statin dosage of 5,400 mg, Q2: statin dosage of 11,900 mg, Q3: statin dosage of 28,000 mg

<sup>b</sup> Kruskal-Wallis test

<sup>c</sup> One-way ANOVA

<sup>d</sup> Chi-Square test

† Tukey-Kramer test significant: non-statin group vs. group 1, non-statin group vs. group 2, non-statin group vs. group 3, non-statin group vs. group 4, group 1 vs. group 4, and group 2 vs. group 4

<sup>‡</sup> Tukey-Kramer test significant: all comparisons were significant

CCI: Charlson comorbidity index, USD: United States dollar, SD: standard deviation